Monitoring abnormal laboratory values as antecedents to drug-induced injury

Journal of Trauma - Injury, Infection and Critical Care

Volumn 59, Issue 6, 2005, Pages 1457-1462

  Kane Gill, Sandra L ^a   Dasta, Joseph F ^b   Schneider, Philip J ^b   Cook, Charles H ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Adverse drug events; Critically ill; Drug related hazardous conditions; Intensive care unit; Patient safety

Indexed keywords

ACETAZOLAMIDE; ADRENALIN; ALANINE AMINOTRANSFERASE; AMPHOTERICIN B; ASPARTATE AMINOTRANSFERASE; CAPTOPRIL; CREATININE; CYCLOSPORIN; ELECTROLYTE; ENOXAPARIN; FAMOTIDINE; FUROSEMIDE; GLUCOSE; HEPARIN; INSULIN; LIVER ENZYME; MAGNESIUM; MANNITOL; MILRINONE; NORADRENALIN; PIPERACILLIN PLUS TAZOBACTAM; POLYSTYRENESULFONATE SODIUM; POTASSIUM; SALBUTAMOL; SPIRONOLACTONE; SULTAMICILLIN; TOBRAMYCIN; VANCOMYCIN;

ACCIDENT PREVENTION; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); DIAGNOSTIC VALUE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG RELATED HAZARDOUS CONDITION; DRUG SAFETY; ELECTROLYTE BLOOD LEVEL; EVALUATION; FEMALE; HUMAN; HYPERKALEMIA; HYPERMAGNESEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INTENSIVE CARE; LABORATORY DIAGNOSIS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; BLOOD GLUCOSE; CREATININE; DRUG THERAPY; DRUG TOXICITY; ELECTROLYTES; FEMALE; HUMANS; INTENSIVE CARE; LIVER; MALE; MIDDLE AGED; PLATELET COUNT; PROSPECTIVE STUDIES;

EID: 33646190678     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ta.0000196009.42623.50     Document Type: Article

References (19)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200-1205.
2. Bates DW. Medication errors. how common are they and what can be done to prevent them? Drug Saf. 1996;15:303-310.
3. Lazarus HM, Fox J, Evans RS, et al. Adverse drug events in trauma patients. J Trauma. 2003;54:337-343.
4. Kohn LT, Corrigan JM, Donaldson MS. Executive Summary. To Err is Huma: Building a Safer Health System. Washington, D.C.: National Academy Press;1999:1-14.
5. Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmondson A, Leape LL. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general units. Crit Care Med. 1997;25:1289-1297.
6. Brilli RJ, Spevetz A, Branson RD, et al. The American College of Critical Care Medicine Task Force on models of crucial care delivery. The American College of Critical Care Medician Guideline for the definition of an intensivist and the practice of critical care medicine. Crit Care Med. 2001;29:2007-2019.
7. Leape LL. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991;324:377-384.
8. Christopherson RC, Smith KEV. Clinical Laboratory Tests. In: Boh LE, ed. Clinical Clerkship Manual. Vancouver, Washington: Applied Therapeutics; 1993:5.1-5.63.
9. Hartwig SC, Denger SD, Schneider PJ. Severity indexed medication error reporting program. Am J Hosp Pharm. 1991;48:2611-2616.
10. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther. 1977;21:247-54.
11. Kramer MS, Leventhal JM, Hutcinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. JAMA. 1979;242:623-32.
12. World Health Organization. Safety of Medicines-a guide to detecting and reporting adverse drug reactions. http://whqlibdoc.who.int/hq/2002/WHO-EDM_QSM_2002.2.pdf. Accessed December 8, 2005.
13. Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients. results of the Harvard Medical Practice Study I. N Engl J Med. 1991;324:370-376.
14. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. implications for prevention. ADE Prevention Study Group. JAMA. 1995;274:29-34.
15. Wang TJ, Mort EA, Nordberg P, et al. A utilization management intervention to reduce unnecessary testing in the coronary care unit. Arch Intern Med. 2002;162:1885-90.
16. Azaz-Livshits T, Levy M, Sadan B, Shalit M, Geisslinger G, Brune K. Computerized surveillance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol. 1998;45:309-314.
17. Tegeder I, Levy M, Muth-Selbach U, et al. Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol. 1999;47:557-564.
18. Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reaction during hospitalization: computerised monitoring versus stimulated spontaneous reporting. Drug Saf. 2000;22:161-169.
19. Jha AK, Kuperman GJ, Teich JM, et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc. 1998;5:305-314.